Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26026725 | 0.86 | LTA4H (0.42) | LTA4HS1PR1S1PR3SPHK1MMP2 | |
| SCHEMBL26026883 | 0.84 | SIRT1 (0.38) | LTA4H | |
| SCHEMBL29649438 | 0.83 | LTA4H (0.43) | LTA4HS1PR1S1PR3SPHK1 | |
| SCHEMBL26024797 | 0.74 | SPHK1 (0.45) | LTA4HS1PR1S1PR3SPHK1MMP2 | |
| SCHEMBL17805687 | 0.74 | STAT3 (0.42) | LTA4HS1PR1S1PR3SPHK1SPHK2 | |
| SCHEMBL8524841 | 0.73 | HTT (0.44) | — | |
| SCHEMBL25357515 | 0.72 | SIRT1 (0.41) | MMP2MMP9 | |
| SCHEMBL25357504 | 0.72 | SIRT1 (0.41) | MMP2MMP9 | |
| SCHEMBL7290278 | 0.72 | RNF4 (0.54) | — | |
| SCHEMBL29649566 | 0.71 | SMN1; SMN2 (0.38) | MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | LTA4H 3377/4885S1PR1 2274/4885S1PR3 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.